上海奥奇医药科技

Shanghai Aoqi Pharmaceutical Technology is a biotechnology research and development company based in Shanghai, China, and operates as a core subsidiary of Shanghai Allist Pharmaceuticals. The company focuses on the discovery and early-stage development of innovative small molecule therapeutics, with a primary emphasis on targeted oncology treatments. It played a critical role in the development of furmonertinib, a third-generation EGFR tyrosine kinase inhibitor that is now commercially available for non-small cell lung cancer. As the R&D arm of the Allist group, the company continues to advance a pipeline of candidates targeting oncogenic drivers such as SHP2, KRAS, and RET to address unmet needs in cancer therapy.